PEMF and Bioregulation Systems for Licensed Practitioners

PEMF (Pulsed Electromagnetic Field) therapy applies low-frequency electromagnetic pulses to the body, typically in the 0.5 to 30 Hz range, using a mat or applicator. The fields pass through soft tissue and bone rather than being absorbed at the skin. Proposed mechanisms, including effects on membrane potential and ion channel activity, remain under investigation. Clinical evidence is condition-specific: see the research library for what has been studied and how each study was graded.

Who this is for: Everyone seeking non-drug wellness support

There is evidence for pain reduction in osteoarthritis. A 2024 systematic review of 17 studies (Cianni et al., 2024, PMID 38610722, grade A-) reported a 60% decrease in VAS pain scores and a 42% improvement in WOMAC scores. Read the full record in our research library.

Who this is for: Those with chronic or acute pain conditions

Source: Cianni et al., 2024. 2024 Meta-Analysis: PEMF for Osteoarthritis. PMID 38610722, grade A-

Sleep is the best supported application in our library. In a four-week double-blind, placebo-controlled study of 101 patients (Pelka et al., 2001, PMID 11697020, grade A-), 70% of treated patients experienced substantial or complete relief of their insomnia. A 2023 multicenter randomized controlled trial (Liao et al., 2023, DOI 10.30773/pi.2022.0362, grade A-) found 69.7% of the PEMF group no longer had clinically significant insomnia, against 35.1% on sham.

Who this is for: Those with insomnia, poor sleep quality, or sleep disorders

Source: Pelka et al., 2001. Impulse Magnetic-Field Therapy for Insomnia. PMID 11697020, grade A-

Source: Liao et al., 2023. Pulse Magnetic Therapy for Insomnia: Multicenter RCT. DOI 10.30773/pi.2022.0362, grade A-

BioReg devices are FDA registered. Registration is a facility and product listing status, not a clearance or an approval, and is not a finding of safety or efficacy. The FDA has cleared specific PEMF devices for specific indications. In 1979, PEMF was approved for non-union bone fractures. Subsequent approvals include post-surgical pain/edema, muscle stimulation, and depression (transcranial magnetic stimulation). Clearance is device- and indication-specific, not blanket approval for all PEMF uses.

Who this is for: Those researching regulatory status

There is no FDA category called clinical-grade. The term is a marketing convention, not a regulatory tier, and any manufacturer can apply it. In practice, practitioners use it to distinguish devices built for professional settings from consumer wellness products. The differences that matter are measurable: number of independently driven output channels, whether programs are fixed or practitioner-editable, session logging and documentation, multi-patient capacity, included training, and service and warranty terms. Field intensity varies widely across both categories and is not by itself a reliable indicator.

Who this is for: Practitioners and buyers comparing device categories

BioReg devices run from $1,495 to $28,995 depending on configuration. Nesta Child: from $1,495. Nesta Metabalance: from $2,395. Nesta Pro Home: from $2,395. Nesta Pro: from $3,995. SanoCenter: $10,550 to $17,995. CellCom: pricing by consultation. CellCom is quoted by consultation, with a published top system configuration of $28,995. Configuration options, pad sizes, and warranty tiers change the final figure. Compare every device and price side by side at /products/compare.

Who this is for: Buyers comparing prices across the line

The line is six devices. For clinical use: Nesta Pro, the practitioner system with 48 practitioner-editable programs, from $3,995; SanoCenter, a clinic platform running 142 automated programs across as many as 64 concurrent stations, $10,550 to $17,995; and CellCom, the flagship biofeedback system, priced by consultation. The home line is Nesta Child from $1,495, Nesta Metabalance from $2,395, and Nesta Pro Home from $2,395. All are European-engineered and carry two years on the device and one year on accessories.

Who this is for: Practitioners selecting equipment

Yes. Home devices are financed through Affirm at checkout, with estimated payments from $51.82 per month on the Nesta Child and from $83.02 per month on the Nesta Metabalance. Those estimates assume 15% APR over 36 months; your actual rate (0 to 36% APR, subject to credit approval) and term (3 to 36 months) are set by Affirm at checkout based on credit qualification, and a down payment may be required. Affirm caps a single transaction at $5,000, so configurations above that ceiling, including Nesta Pro Premium at $5,995, carry no direct financing link and no published monthly figure. Financing for those is available by inquiry: contact us to discuss options. Practitioner capital financing for SanoCenter and CellCom is a separate lender program quoted at 9% APR over 36 months with $0 down, available to licensed practitioners only.

Who this is for: Buyers exploring payment and financing options